Bonzun AB (publ) (BONZUN.ST)
SEK 0.01
(-2.78%)
SEK 0.01
(-2.78%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.73 Million SEK | 151.24% |
| 2022 | 1.08 Million SEK | 202.94% |
| 2021 | 359.48 Thousand SEK | -35.22% |
| 2020 | 554.88 Thousand SEK | -57.93% |
| 2019 | 1.31 Million SEK | 21.28% |
| 2018 | 1.08 Million SEK | 20.07% |
| 2017 | 905.74 Thousand SEK | 5285.89% |
| 2016 | 16.81 Thousand SEK | -72.59% |
| 2015 | 61.36 Thousand SEK | 0.0% |
| 2014 | - SEK | -100.0% |
| 2013 | 50 Thousand SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 30 Thousand TRY | -52.38% |
| 2024 Q1 | 63 Thousand SEK | -70.0% |
| 2023 Q4 | 210 Thousand SEK | -92.62% |
| 2023 Q1 | 800 Thousand SEK | 83.49% |
| 2023 Q2 | 319 Thousand SEK | -60.13% |
| 2023 FY | 2.73 Million SEK | 151.24% |
| 2023 Q3 | 2.84 Million SEK | 791.54% |
| 2022 Q4 | 436 Thousand SEK | 87.93% |
| 2022 Q2 | 201 Thousand SEK | -8.64% |
| 2022 Q1 | 220 Thousand SEK | 182.24% |
| 2022 FY | 1.08 Million SEK | 202.94% |
| 2022 Q3 | 232 Thousand SEK | 15.42% |
| 2021 Q3 | 374 Thousand SEK | 0.0% |
| 2021 FY | 359.48 Thousand SEK | -35.22% |
| 2021 Q4 | -267.52 Thousand SEK | -171.53% |
| 2020 FY | 554.88 Thousand SEK | -57.93% |
| 2020 Q3 | 26 Thousand SEK | 0.0% |
| 2020 Q4 | 159.88 Thousand SEK | 514.93% |
| 2019 FY | 1.31 Million SEK | 21.28% |
| 2018 FY | 1.08 Million SEK | 20.07% |
| 2017 FY | 905.74 Thousand SEK | 5285.89% |
| 2016 FY | 16.81 Thousand SEK | -72.59% |
| 2015 FY | 61.36 Thousand SEK | 0.0% |
| 2014 FY | - SEK | -100.0% |
| 2013 FY | 50 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aino Health AB (publ) | 23.91 Million SEK | 88.561% |
| Kontigo Care AB (publ) | 28.94 Million SEK | 90.549% |
| Medhelp Care Aktiebolag (publ) | 84.08 Million SEK | 96.746% |
| RaySearch Laboratories AB (publ) | 1.02 Billion SEK | 99.732% |
| Surgical Science Sweden AB (publ) | 882.85 Million SEK | 99.69% |